Showing results (71-80 of 90) with videos related to
Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast CancerRachel O Abelman, Bogang Wu, Haley Barnes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2020
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast CancerPingping Mao, Ofir Cohen, Kailey J Kowalski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Sheng Sun, Nayana Thimmiah, et al.NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 29, 2024
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatmentAntonino Glaviano, Seth A Wander, Richard D Baird, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, et al.Cancer Research|January 9, 2016
Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant ProgressionManuel Picon-Ruiz, Chendong Pan, Katherine Drews-Elger, et al.Journal of the American Chemical Society|May 3, 2017
Carba-cyclophellitols Are Neutral Retaining-Glucosidase InhibitorsThomas J M Beenakker, Dennis P A Wander, Wendy A Offen, et al.Therapeutic Advances in Medical Oncology|September 2, 2022
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancerElyssa Denault, Erika Nakajima, Vivek Naranbhai, et al.JCO Oncology Practice|November 3, 2023
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community CollaborationLaura M Spring, Lindsey Mortensen, Elizabeth Abraham, et al.Pageof 9